BerandaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$34,07
Rentang tahun
R$25,64 - R$44,18
Kapitalisasi pasar
12,91Â M USD
Volume Rata-Rata
182,00
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 805,50Â jt | 28,33% |
Biaya operasional | 302,50Â jt | 5,11% |
Penghasilan bersih | 153,70Â jt | 49,08% |
Margin laba bersih | 19,08 | 16,13% |
Penghasilan per saham | 1,88 | 11,24% |
EBITDA | 234,70Â jt | 54,31% |
Tarif pajak efektif | 35,80% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,48Â M | 37,57% |
Total aset | 4,63Â M | 24,55% |
Total liabilitas | 1,38Â M | 22,09% |
Total ekuitas | 3,25 M | — |
Saham yang beredar | 100,36 jt | — |
Harga terhadap nilai buku | 1,05 | — |
Tingkat pengembalian aset | 12,77% | — |
Tingkat pengembalian modal | 15,76% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 153,70Â jt | 49,08% |
Kas dari operasi | 388,40Â jt | 60,16% |
Kas dari investasi | -52,90Â jt | 22,55% |
Kas dari pembiayaan | 37,30Â jt | 112,86% |
Perubahan kas bersih | 372,80Â jt | 421,10% |
Arus kas bebas | 312,50Â jt | 15,90% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
2.000
